Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ATRS's Cash-to-Debt is ranked higher than
97% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ATRS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ATRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.68
ATRS's Equity-to-Asset is ranked higher than
66% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ATRS: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
ATRS' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.09  Med: 0.52 Max: 0.93
Current: 0.68
-4.09
0.93
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
96% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. ATRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 6.87
Beneish M-Score: -2.94
WACC vs ROIC
5.78%
-135.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -46.18
ATRS's Operating Margin % is ranked lower than
81% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. ATRS: -46.18 )
Ranked among companies with meaningful Operating Margin % only.
ATRS' s Operating Margin % Range Over the Past 10 Years
Min: -215.47  Med: -75.92 Max: -26.96
Current: -46.18
-215.47
-26.96
Net Margin % -46.60
ATRS's Net Margin % is ranked lower than
80% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. ATRS: -46.60 )
Ranked among companies with meaningful Net Margin % only.
ATRS' s Net Margin % Range Over the Past 10 Years
Min: -224.17  Med: -75.04 Max: -26.66
Current: -46.6
-224.17
-26.66
ROE % -44.14
ATRS's ROE % is ranked lower than
80% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. ATRS: -44.14 )
Ranked among companies with meaningful ROE % only.
ATRS' s ROE % Range Over the Past 10 Years
Min: -127.89  Med: -53.09 Max: -19.42
Current: -44.14
-127.89
-19.42
ROA % -31.77
ATRS's ROA % is ranked lower than
80% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ATRS: -31.77 )
Ranked among companies with meaningful ROA % only.
ATRS' s ROA % Range Over the Past 10 Years
Min: -52.7  Med: -33.9 Max: -15.37
Current: -31.77
-52.7
-15.37
ROC (Joel Greenblatt) % -139.43
ATRS's ROC (Joel Greenblatt) % is ranked lower than
80% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.86 vs. ATRS: -139.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2034.35  Med: -734.8 Max: -141.9
Current: -139.43
-2034.35
-141.9
3-Year Revenue Growth Rate 27.70
ATRS's 3-Year Revenue Growth Rate is ranked higher than
95% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ATRS: 27.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATRS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -63.5  Med: 10.8 Max: 93.3
Current: 27.7
-63.5
93.3
3-Year EBITDA Growth Rate -3.50
ATRS's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. ATRS: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATRS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: -7.5 Max: 80.8
Current: -3.5
-41.5
80.8
GuruFocus has detected 7 Warning Signs with Antares Pharma Inc $ATRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATRS Guru Trades in Q1 2016

Chuck Royce 406,900 sh (+318.26%)
Jim Simons 2,231,169 sh (+61.04%)
First Eagle Investment 20,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

ATRS Guru Trades in Q2 2016

Jim Simons 2,717,852 sh (+21.81%)
First Eagle Investment 20,000 sh (unchged)
Chuck Royce 406,900 sh (unchged)
» More
Q3 2016

ATRS Guru Trades in Q3 2016

First Eagle Investment 20,000 sh (unchged)
Chuck Royce 406,900 sh (unchged)
Jim Simons 2,674,341 sh (-1.60%)
» More
Q4 2016

ATRS Guru Trades in Q4 2016

Jim Simons 2,859,341 sh (+6.92%)
First Eagle Investment 20,000 sh (unchged)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:PLSE, NAS:MLAB, NAS:LMAT, NAS:STAA, OTCPK:GMDTF, OTCPK:AMSJF, NAS:ENTL, NAS:ELGX, OTCPK:CLHLF, AMEX:CRHM, NAS:NVCR, NAS:ANGO, NAS:UTMD, NAS:ATRC, NAS:CFMS, NAS:DSCI, NAS:MBOT, NAS:SIEN, NAS:OSUR, AMEX:TRXC » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors.

Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.

Top Ranked Articles about Antares Pharma Inc

Weekly CFO Buys Highlights Insiders buy Antares Pharma,Sonoma Pharmaceuticals, Versum Materials
According to GuruFocus Insider Data, the recent chief financial officer (CFO) buys were: Antares Pharma Inc. (NASDAQ:ATRS), Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) and Versum Materials Inc. (NYSE:VSM). Read more...

Ratios

vs
industry
vs
history
PB Ratio 9.48
ATRS's PB Ratio is ranked lower than
84% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.39 vs. ATRS: 9.48 )
Ranked among companies with meaningful PB Ratio only.
ATRS' s PB Ratio Range Over the Past 10 Years
Min: 1.83  Med: 7.65 Max: 24.29
Current: 9.48
1.83
24.29
PS Ratio 8.17
ATRS's PS Ratio is ranked lower than
84% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRS: 8.17 )
Ranked among companies with meaningful PS Ratio only.
ATRS' s PS Ratio Range Over the Past 10 Years
Min: 2.13  Med: 11.48 Max: 31.27
Current: 8.17
2.13
31.27
EV-to-EBIT -16.62
ATRS's EV-to-EBIT is ranked lower than
99.99% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.63 vs. ATRS: -16.62 )
Ranked among companies with meaningful EV-to-EBIT only.
ATRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.9  Med: -9.9 Max: -1
Current: -16.62
-121.9
-1
EV-to-EBITDA -18.01
ATRS's EV-to-EBITDA is ranked lower than
99.99% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.65 vs. ATRS: -18.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.8  Med: -10.45 Max: -1.1
Current: -18.01
-126.8
-1.1
Current Ratio 2.27
ATRS's Current Ratio is ranked lower than
53% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.37 vs. ATRS: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.24 Max: 12.01
Current: 2.27
0.21
12.01
Quick Ratio 2.01
ATRS's Quick Ratio is ranked higher than
64% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ATRS: 2.01 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.01 Max: 11.45
Current: 2.01
0.21
11.45
Days Inventory 77.27
ATRS's Days Inventory is ranked higher than
80% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. ATRS: 77.27 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s Days Inventory Range Over the Past 10 Years
Min: 11.13  Med: 33.79 Max: 200.11
Current: 77.27
11.13
200.11
Days Sales Outstanding 63.41
ATRS's Days Sales Outstanding is ranked lower than
51% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.14 vs. ATRS: 63.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.3  Med: 52.28 Max: 86.08
Current: 63.41
18.3
86.08
Days Payable 99.87
ATRS's Days Payable is ranked higher than
77% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.97 vs. ATRS: 99.87 )
Ranked among companies with meaningful Days Payable only.
ATRS' s Days Payable Range Over the Past 10 Years
Min: 85.36  Med: 133.16 Max: 380
Current: 99.87
85.36
380

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
ATRS's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ATRS: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATRS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.2  Med: -15.5 Max: -0.7
Current: -6.4
-140.2
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 69.00
ATRS's Price-to-Net-Cash is ranked lower than
94% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.99 vs. ATRS: 69.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.13  Med: 12.77 Max: 85
Current: 69
2.13
85
Price-to-Net-Current-Asset-Value 17.25
ATRS's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 106 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.27 vs. ATRS: 17.25 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.8  Med: 10.64 Max: 34
Current: 17.25
1.8
34
Price-to-Tangible-Book 10.18
ATRS's Price-to-Tangible-Book is ranked lower than
76% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. ATRS: 10.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.56  Med: 8.52 Max: 30.36
Current: 10.18
1.56
30.36
Price-to-Median-PS-Value 0.71
ATRS's Price-to-Median-PS-Value is ranked higher than
77% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ATRS: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.7 Max: 2.46
Current: 0.71
0.08
2.46
Earnings Yield (Greenblatt) % -6.02
ATRS's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ATRS: -6.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33.02  Med: 0 Max: 0
Current: -6.02
-33.02
0

More Statistics

Revenue (TTM) (Mil) $52.22
EPS (TTM) $ -0.16
Beta0.45
Short Percentage of Float1.74%
52-Week Range $0.70 - 2.90
Shares Outstanding (Mil)155.24

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.05
EPS without NRI ($) 0.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlights Dec 13 2016 
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
ATRS: 2016 Financial and Operational Results Mar 21 2017
Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
ANTARES PHARMA, INC. Financials Mar 18 2017
Antares Pharma, Inc. :ATRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016... Mar 15 2017
Antares Pharma reports 4Q loss Mar 14 2017
Antares Pharma reports 4Q loss Mar 14 2017
Q4 2016 Antares Pharma Inc Earnings Release - Before Market Open Mar 14 2017
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 14 2017
Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results Mar 14 2017
Antares Pharma to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host... Mar 06 2017
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Mar 06 2017
Antares Pharma to Present at the Cowen and Company 37th Annual Healthcare Conference Feb 28 2017
Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone Feb 27 2017
Biotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ACADIA... Jan 31 2017
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 27 2017
Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : January 24, 2017 Jan 24 2017
Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : January 23,... Jan 23 2017
ETFs with exposure to Antares Pharma, Inc. : January 20, 2017 Jan 20 2017
ETFs with exposure to Antares Pharma, Inc. : January 3, 2017 Jan 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)